NQO1 C609T Polymorphism is Associated with Coronary Artery Disease in a Gender-Dependent Manner
Tóm tắt
Findings on the association of NQO1 C609T polymorphism in the NQO1 gene and cardiovascular disease susceptibility are controversial. The objective of the current study was to examine the relationship between this polymorphism and the presence and severity of angiographically determined coronary artery disease (CAD). One-hundred and forty-five patients with newly diagnosed angiographically documented CAD (≥50 % luminal stenosis of any coronary vessel) as case group were compared to 139 controls (subjects with no luminal stenosis at coronary arteries). The presence of C609T polymorphism was analyzed using polymerase chain reaction-based restriction fragment length polymorphism. Among total population, those with combined CT/TT (T allele carrier) genotype showed a trend toward lower odds of CAD compared to those with CC (wild type) genotype, but it did not reach a statistically significant level (p = 0.061). When data were analyzed separately for men or women, CT + TT group as compared to CC genotype was associated with decreased odds of CAD in women (adjusted OR 0.4, 95 % CI 0.2–0.9; p = 0.043), but not in men (adjusted OR 0.8, 95 % CI 0.3–1.9; p = 0.612). The C609T polymorphism within NQO1 is independently associated with CAD in women, but no association was observed in whole study population or in men.
Tài liệu tham khảo
World Health Organization. (2014). Global status report on noncommunicable diseases. Geneva, Switzerland: World Health Organization.
Wang, Q. (2005). Molecular genetics of coronary artery disease. Current Opinion in Cardiology, 20, 182–188.
Topol, E. J. (2005). Simon Dack lecture. The genomic basis of myocardial infarction. Journal of the American College of Cardiology, 46, 1456–1465.
Siegel, D., Schuff, M., Oswald, F., Cao, Y., & Knochel, W. (2009). Functional dissection of XDppa2/4 structural domains in Xenopus development. Mechanisms of Development, 126, 974–989.
Chen, C., Reece, D. E., Siegel, D., Niesvizky, R., Boccia, R. V., Stadtmauer, E. A., et al. (2009). Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. British Journal of Haematology, 146, 164–170.
Siegel, D., & Ross, D. (2000). Immunodetection of NAD(P)H: quinone oxidoreductase 1 (NQO1) in human tissues. Free Radical Biology and Medicine, 29, 246–253.
Zhu, H., & Li, Y. (2012). NAD(P)H:quinone oxidoreductase 1 and its potential protective role in cardiovascular diseases and related conditions. Cardiovascular Toxicology, 12, 39–45.
Cadenas, E. (1995). Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochemical Pharmacology, 49, 127–140.
Traver, R. D., Siegel, D., Beall, H. D., Phillips, R. M., Gibson, N. W., Franklin, W. A., et al. (1997). Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). British Journal of Cancer, 75, 69–75.
Siegel, D., Anwar, A., Winski, S. L., Kepa, J. K., Zolman, K. L., & Ross, D. (2001). Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Molecular Pharmacology, 59, 263–268.
Siegel, D., McGuinness, S. M., Winski, S. L., & Ross, D. (1999). Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics, 9, 113–121.
Lajin, B., & Alachkar, A. (2013). The NQO1 polymorphism C609T (Pro187Ser) and cancer susceptibility: A comprehensive meta-analysis. British Journal of Cancer, 109, 1325–1337.
Yang, Y., Zhang, Y., Wu, Q., Cui, X., Lin, Z., Liu, S., et al. (2014). Clinical implications of high NQO1 expression in breast cancers. Journal of Experimental and Clinical Cancer Research, 33, 14.
Han, S. J., Kang, E. S., Kim, H. J., Kim, S. H., Chun, S. W., Ahn, C. W., et al. (2009). The C609T variant of NQO1 is associated with carotid artery plaques in patients with type 2 diabetes. Molecular Genetics and Metabolism, 97, 85–90.
Martin, N. J., Collier, A. C., Bowen, L. D., Pritsos, K. L., Goodrich, G. G., Arger, K., et al. (2009). Polymorphisms in the NQO1, GSTT and GSTM genes are associated with coronary heart disease and biomarkers of oxidative stress. Mutation Research, 674, 93–100.
Shyu, H. Y., Fong, C. S., Fu, Y. P., Shieh, J. C., Yin, J. H., Chang, C. Y., et al. (2010). Genotype polymorphisms of GGCX, NQO1, and VKORC1 genes associated with risk susceptibility in patients with large-artery atherosclerotic stroke. Clinica Chimica Acta, 411, 840–845.
Gensini, G. G. (1983). A more meaningful scoring system for determining the severity of coronary heart disease. American Journal of Cardiology, 51, 606.
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry, 18, 499–502.
Naoe, T., Takeyama, K., Yokozawa, T., Kiyoi, H., Seto, M., Uike, N., et al. (2000). Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clinical Cancer Research, 6, 4091–4095.
Hur, K. Y., Kim, S. H., Choi, M. A., Williams, D. R., Lee, Y. H., Kang, S. W., et al. (2010). Protective effects of magnesium lithospermate B against diabetic atherosclerosis via Nrf2-ARE-NQO1 transcriptional pathway. Atherosclerosis, 211, 69–76.
Walter, M. F., Jacob, R. F., Bjork, R. E., Jeffers, B., Buch, J., Mizuno, Y., et al. (2008). Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: The PREVENT study. Journal of the American College of Cardiology, 51, 1196–1202.
Nebert, D. W., Roe, A. L., Vandale, S. E., Bingham, E., & Oakley, G. G. (2002). NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: A HuGE review. Genetic Medicine, 4, 62–70.
Biramijamal, F., Sanati, M. H., Banoei, M. M., Bayat, B., Arjmand, S., & Farhud, D. (2006). Genetic polymorphism analysis of NAD (P) H:quinone oxidoreductase 1 in different Iranian ethnic groups. Current Science-Bangalore, 91, 1065.
Kelsey, K., Ross, D., Traver, R., Christiani, D., Zuo, Z., Spitz, M., et al. (1997). Ethnic variation in the prevalence of a common NAD (P) H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. British Journal of Cancer, 76, 852.
Yu, X., Liu, J., Zhu, H., Xia, Y., Gao, L., Dong, Y., et al. (2014). Synergistic association of DNA repair relevant gene polymorphisms with the risk of coronary artery disease in northeastern Han Chinese. Thrombosis Research, 133, 229–234.
Kim, S. Y., Jeoung, N. H., Oh, C. J., Choi, Y. K., Lee, H. J., Kim, H. J., et al. (2009). Activation of NAD(P)H:quinone oxidoreductase 1 prevents arterial restenosis by suppressing vascular smooth muscle cell proliferation. Circulation Research, 104, 842–850.
de Visser, M. C., Roshani, S., Rutten, J. W., van Hylckama Vlieg, A., Vos, H. L., Rosendaal, F. R., et al. (2011). Haplotypes of VKORC1, NQO1 and GGCX, their effect on activity levels of vitamin K-dependent coagulation factors, and the risk of venous thrombosis. Thrombosis and Haemostasis, 106, 563–565.
Ramprasath, T., Murugan, P. S., Kalaiarasan, E., Gomathi, P., Rathinavel, A., & Selvam, G. S. (2012). Genetic association of glutathione peroxidase-1 (GPx-1) and NAD(P)H:quinone oxidoreductase 1(NQO1) variants and their association of CAD in patients with type-2 diabetes. Molecular and Cellular Biochemistry, 361, 143–150.
Alard, A., Fabre, B., Anesia, R., Marboeuf, C., Pierre, P., Susini, C., et al. (2010). NAD(P)H quinone-oxydoreductase 1 protects eukaryotic translation initiation factor 4GI from degradation by the proteasome. Molecular and Cellular Biology, 30, 1097–1105.
Cheng, Y., Li, J., Martinka, M., & Li, G. (2010). The expression of NAD(P)H:quinone oxidoreductase 1 is increased along with NF-kappaB p105/p50 in human cutaneous melanomas. Oncology Reports, 23, 973–979.
Augustine, L. M., Fisher, C. D., Lickteig, A. J., Aleksunes, L. M., Slitt, A. L., & Cherrington, N. J. (2008). Gender divergent expression of Nqo1 in Sprague Dawley and August Copenhagen x Irish rats. Journal of Biochemical and Molecular Toxicology, 22, 93–100.
Bauer, A. K., Faiola, B., Abernethy, D. J., Marchan, R., Pluta, L. J., Wong, V. A., et al. (2003). Genetic susceptibility to benzene-induced toxicity: Role of NADPH: quinone oxidoreductase-1. Cancer Research, 63, 929–935.